High-altitude headache and acute mountain sickness;Cefalea de elevada altitud y mal de altura

Neurologia

Volumn 29, Issue 9, 2014, Pages 533-540

  Carod Artal, F J ^a  

^a HOSPITAL VIRGEN DE LA LUZ   (Spain)

Author keywords

Acute mountain sickness; Cerebral oedema; Headache; Lake Louise Questionnaire

Indexed keywords

ACETAZOLAMIDE; IBUPROFEN; PARACETAMOL; STEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ALTITUDE ACCLIMATIZATION; ALTITUDE DISEASE; ANOREXIA; BRAIN EDEMA; BRAIN HYPOXIA; CAPILLARY PRESSURE; CORPUS CALLOSUM; CYTOKINE RELEASE; DIZZINESS; FATIGUE; HEADACHE; HEMODYNAMICS; HIGH ALTITUDE HEADACHE; HUMAN; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; SHORT SURVEY; SLEEP DISORDER; STEROID THERAPY; VASODILATATION; WHITE MATTER; ALTITUDE SICKNESS; COMPLICATION; DIFFERENTIAL DIAGNOSIS;

ALTITUDE SICKNESS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN EDEMA; DIAGNOSIS, DIFFERENTIAL; HEADACHE; HUMANS; IBUPROFEN;

EID: 84922430126     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2012.04.015     Document Type: Short Survey

References (59)

1. Rennie D. The great breathlessness mountains. JAMA 1986, 256:81-82.
2. Bert P. La pression barometrique. Paris: G Masson, 1878. [Reedición Paris: The Centre National de la Recherche Scientifique; 1979.].
3. Ravenhill T.H. Some experiences of mountain sickness in the Andes. J Trop Med Hyg 1913, 16:313-320.
4. Wilson M.H., Newman S., Imray C.H. The cerebral effects of ascent to high altitudes. Lancet Neurol 2009, 8:175-191.
5. Hackett P.H., Roach R.C. High-altitude illness. N Engl J Med 2001, 345:107-114.
6. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004, 24(Suppl 1):S9-S151. Headache Classification Subcommittee of the International Headache Society.
7. Imray C., Wright A., Subudhi A., Roach R. Acute mountain sickness: pathophysiology, prevention, and treatment. Prog Cardiovasc Dis 2010, 52:467-484.
8. Silber E., Sonnenberg P., Collier D.J., Pollar A.J., Murdoch D.R., Goadsby P.J. Clinical features of headache at altitude. A prospective study. Neurology 2003, 60:1167-1171.
9. Serrano Dueñas M. High altitude headache. A prospective study of its clinical characteristics. Cephalalgia 2005, 25:1110-1116.
10. Imray C.H., Pattinson K.T., Myers S., Chan C.W., Hoar H., Brearey S., et al. Intrapulmonary and intracardiac shunting with exercise at altitude. Wilderness Environ Med 2008, 19:199-204.
11. Mampreso E., Maggioni F., Viaro F., Disco C., Zanchin G. Efficacy of oxygen inhalation in sumatriptan refractory "high altitude" cluster headache attacks. J Headache Pain 2009, 10:465-467.
12. Pesce C., Leal C., Pinto H., González G., Maggiorini M., Schneider M., et al. Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m). High Alt Med Biol 2005, 6:158-166.
13. Lawley J.S. Identifying the possible risk factors for high-altitude headache in mountaineers. Cephalalgia 2011, 31:1677-1678.
14. Burtscher M., Mairer K., Wille M., Broessner G. Risk factors for high-altitude headache in mountaineers. Cephalalgia 2011, 31:706-711.
15. Van Osta A., Moraine J.J., Mélot C., Mairbäurl H., Maggiorini M., Naeije R. Effects of high altitude exposure on cerebral hemodynamics in normal subjects. Stroke 2005, 36:557-560.
16. Wilson M.H., Edsell M.E., Davagnanam I., Hirani S.P., Martin D.S., Levett D.Z., et al. Cerebral artery dilatation maintains cerebral oxygenation at extreme altitude and in acute hypoxia-an ultrasound and MRI study. J Cereb Blood Flow Metab 2011, 31:2019-2029. Caudwell Xtreme Everest Research Group.
17. Cochand N.J., Wild M., Brugniaux J.V., Davies P.J., Evans K.A., Wise R.G., et al. Sea-level assessment of dynamic cerebral autoregulation predicts susceptibility to acute mountain sickness at high altitude. Stroke 2011, 42:3628-3630.
18. Sanchez del Rio M., Moskowitz M.A. High altitude headache. Lessons from headaches at sea level. Adv Exp Med Biol 1999, 474:145-153.
19. Queiroz L.P., Rapoport A.M. High-altitude headache. Curr Pain Headache Rep 2007, 11:293-296.
20. Vardy J., Judge K. Acute mountain sickness and ascent rates in trekkers above 2500 m in the Nepali Himalaya. Aviat Space Environ Med 2006, 77:742-744.
21. Wright A.D. Medicine at high altitude. Clin Med 2006, 6:604-608. Birmingham Medical Research Expeditionary Society.
22. Woods D.R., Allen S., Betts T.R., Gardiner D., Montgomery H., Morgan J.M., et al. High altitude arrhythmias. Cardiology 2008, 111:239-246.
23. Suzuki K., Kizaki T., Hitomi Y., Nukita M., Kimoto K., Miyazawa N., et al. Genetic variation in hypoxia inducible factor 1alpha and its possible association with high altitude adaptation in Sherpas. Med Hypotheses 2003, 61:385-389.
24. Clarke C. Acute mountain sickness: medical problems associated with acute and subacute exposure to hypobaric hypoxia. Postgrad Med J 2006, 82:748-753.
25. Yamakawa M., Liu L.X., Date T., Belanger A.J., Vincent K.A., Akita G.Y., et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 2003, 93:664-673.
26. Severinghaus J.W. Hypothesis: angiogenesis cytokines in high altitude cerebral oedema. Acta Anaesthesiol Scand Suppl 1995, 107:177-178.
27. Roach R.C., Bartsch P., Hackett P.H., Oelz O. The Lake Louise Acute Mountain Sickness scoring system. Hypoxia and Molecular Medicine 1993, 273-274. the Lake Louise AMS Scoring Consensus committee, Queen City Press, Burlington, Vt. J.R. Sutton, C.S. Houston, G. Coates (Eds.).
28. Dellasanta P., Gaillard S., Loutan L., Kayser B. Comparing questionnaires for the assessment of acute mountain sickness. High Alt Med Biol 2007, 8:184-191.
29. Carod-Artal F.J., Ezpeleta Echávarri D., Guerrero Peral A.L. Propiedades métricas de la versión española del Cuestionario de Mal de Altura del Lago Louise. Neurología 2011, 26:337-342.
30. Sampson J.B., Kobrick J.L. The environmental symptoms questionnaire: Revisions and new field data. Aviat Space Environ Med 1980, 51:872-877.
31. Wu T.Y., Ding S.Q., Liu J.L., Yu M.T., Jia J.H., Chai Z.C., et al. Who should not go high: chronic disease and work at altitude during construction of the Qinghai-Tibet railroad. High Alt Med Biol 2007, 8:88-107.
32. Ren Y., Fu Z., Shen W., Jiang P., He Y., Peng S., et al. Incidence of high altitude illnesses among unacclimatized persons who acutely ascended to Tibet. High Alt Med Biol 2010, 11:39-42.
33. Fiore D.C., Hall S., Shoja P. Altitude illness: risk factors, prevention, presentation, and treatment. Am Fam Physician 2010, 82:1103-1110.
34. Hackett P.H., Roach R.C. High altitude cerebral edema. High Alt Med Biol 2004, 5:136-146.
35. Kallenberg K., Bailey D.M., Christ S., Mohr A., Roukens R., Menold E., et al. Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute sickness. J Cereb Blood Flow Metab 2007, 27:1064-1071.
36. Hackett P.H., Yarnell P.R., Hill R., Reynard K., Heit J., McCormick J. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. JAMA 1998, 280:1920-1925.
37. Kallenberg K., Dehnert C., Dorfler A., Schellinger P.D., Bailey D.M., Knauth M., et al. Microhemorrhages in nonfatal high-altitude cerebral edema. J Cereb Blood Flow Metab 2008, 28:1635-1642.
38. Wilson M.H., Imray C.H., Hargens A.R. The headache of high altitude and microgravity-similarities with clinical syndromes of cerebral venous hypertension. High Alt Med Biol 2011, 12:379-386.
39. Basnyat B., Wu T., Gertsch J.H. Neurological conditions at altitude that fall outside the usual definition of altitude sickness. High Alt Med Biol 2004, 5:171-179.
40. Song S.Y., Asaji T., Tanizaki Y., Fujimaki T., Matsutani M., Okeda R. Cerebral thrombosis at altitude: its pathogenesis and the problems of prevention and treatment. Aviat Space Environ Med 1986, 57:71-76.
41. Dickinson J., Health D., Gosney J., Williams D. Altitude-related deaths in seven trekkers in the Himalayas. Thorax 1983, 38:646-656.
42. Pelamatti G., Pascotto M., Semenza C. Verbal free recall in high altitude: proper names vs common names. Cortex 2003, 39:97-103.
43. Nelson T.O., Dunlosky J., White D.M., Steinberg J., Townes B.D., Anderson D. Cognition and metacognition at extreme altitudes on Mount Everest. J Exp Psychol Gen 1990, 119:367-374.
44. Harris N.S., Wenzel R.P., Thomas S.H. High altitude headache: efficacy of acetaminophen vs. ibuprofen in a randomized, controlled trial. J Emerg Med 2003, 24:383-387.
45. Grissom C.K., Roach R.C., Sarnquist F.H., Hackett P.H. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 1992, 116:461-465.
46. Hackett P.H., Roach R.C., Wood R.A., Foutch R.G., Meehan R.T., Rennie D., et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med 1988, 59:950-954.
47. Bärtsch P., Merki B., Hofstetter D., Maggiorini M., Kayser B., Oelz O. Treatment of acute mountain sickness by simulated descent: a randomised controlled trial. BMJ 1993, 306:1098-1101.
48. Wright A., Brearey S., Imray C. High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high-altitude cerebral and pulmonary oedema. Expert Opin Pharmacother 2008, 9:119-127.
49. Schoch H.J., Fischer S., Marti H.H. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002, 125:2549-2557.
50. Gertsch J.H., Lipman G.S., Holck P.S., Merritt A., Mulcahy A., Fisher R.S., et al. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med 2010, 21:236-243.
51. Dumont L., Mardirosoff C., Tramèr M.R. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 2000, 321:267-277.
52. Basnyat B., Gertsch J.H., Holck P.S., Johnson E.W., Luks A.M., Donham B.P., et al. Acetazolamide 125mg BD is not significantly different from 375mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol 2006, 7:17-27.
53. Basnyat B., Holck P.S., Pun M., Halverson S., Szawarski P., Gertsch J., et al. Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness Environ Med 2011, 22:15-22. SPACE Trial Group.
54. Johnson T.S., Rock P.B., Fulco C.S., Trad L.A., Spark R.F., Maher J.T. Prevention of acute mountain sickness by dexamethasone. N Engl J Med 1984, 310:683-686.
55. Basu M., Sawhney R.C., Kumar S., Pal K., Prasad R., Selvamurthy W. Glucocorticoids as prophylaxis against acute mountain sickness. Clin Endocrinol 2002, 57:761-767.
56. Gertsch J.H., Basnyat B., Johnson E.W., Onopa J., Holck P.S. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ 2004, 328:797.
57. Burtscher M., Likar R., Nachbauer W., Philadelphy M. Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ 1998, 316:1057-1058.
58. Jafarian S., Gorouhi F., Salimi S., Lotfi J. Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Ann Neurol 2007, 62:273-277.
59. Küpper T.E., Strohl K.P., Hoefer M., Gieseler U., Netzer C.M., Netzer N.C. Low-dose theophylline reduces symptoms of acute mountain sickness. J Travel Med 2008, 15:307-314.